RT Journal Article
SR Electronic
T1 Stratification of hypertensive COVID-19 patients by quantitative NMR spectroscopy of serum metabolites, lipoproteins and inflammation markers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.20.22283729
DO 10.1101/2022.12.20.22283729
A1 Kazenwadel, Jasmin
A1 Berezhnoy, Georgy
A1 Cannet, Claire
A1 Schäfer, Hartmut
A1 Geisler, Tobias
A1 Rohlfing, Anne-Katrin
A1 Gawaz, Meinrad
A1 Merle, Uta
A1 Trautwein, Christoph
YR 2022
UL http://medrxiv.org/content/early/2022/12/21/2022.12.20.22283729.abstract
AB Background The exact pathophysiology of humans suffering from the multifaceted SARS-CoV-2 infection is not yet conclusively understood and risk stratification is needed. Novel diagnostic approaches like the nuclear magnetic resonance spectroscopy (NMR) based quantification of metabolites, lipoproteins, and inflammation markers has helped to identify typical alterations in the blood serum of COVID-19 patients. However, important confounders such as age, sex, and comorbidities, which strongly influence the metabolome, were often not considered. Therefore, the aim of this NMR study was to consider gender, as well as arterial hypertension (AHT) which affects more than 1.2 billion people worldwide, when investigating COVID-19-positive serum samples in a large age-matched cohort. As AHT is a risk factor for severe COVID-19 disease, this study focuses on comparing metabolomic characteristics of COVID-19 patients with and without AHT.Methods and Findings NMR serum data from 329 COVID-19 patients were compared with 305 individuals from a healthy age and sex-matched control cohort. 134 of the 329 COVID-19 patients were affected by AHT. These were analyzed together with NMR data from 58 hypertensives without COVID-19. In addition to metabolite, lipoprotein, and glycoprotein data from NMR, common laboratory parameters were considered. Statistical comparison of the COVID-19 cohort with the control cohort reproduced results of previous studies. However, several differences emerged when AHT was considered. Especially, the previously described triglyceride-rich lipoprotein profile was no longer observed in COVID-19 patients, nor was an increase in ketone bodies. Typical metabolic changes that were apparent in COVID-19 patients in both sexes and with AHT were an increase in C-reactive protein (CRP) and the ratio of total glycoprotein (Glyc) to supramolecular phospholipids composite (SPC) which is an inflammatory NMR parameter. Further alterations were a decrease in glutamine, leucine, isoleucine, and lysine, citric acid, HDL-4 particles, and total cholesterol. Typical metabolic cardiovascular risk markers could be detected in hypertensive COVID-19 patients, as well as higher inflammatory NMR parameters than in normotensive COVID-19 patients.Conclusion We could show that a more precise picture of COVID-19 blood serum parameters emerge when AHT is considered which accordingly should be included in future studies and would help for a refined patient stratification.Competing Interest StatementCT and GB report a research grant by Bruker BioSpin GmbH.Funding StatementThis project was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)- project number 374031971 - TRR 240.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted according to the Declaration of Helsinki and was approved by the Ethics Committees of Heidelberg Medical University (protocol code S/324/2020), University Hospital Tuebingen (protocol code 141/2018BO2) and University of Wuerzburg (protocol code 52/18).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.NameExtended nameACEIAngiotensin-converting-enzyme inhibitorAHTArterial hypertensionAT1RBAngiotensin-1 receptor blockersAUCArea under the curveBBBeta blockersBCAABranched chained amino acids (leucine, isoleucine, valine)BPBlood pressureBUNBlood urea nitrogenCCBCalcium channel blockersCreatinine.labCreatinine (laboratory report)CRPC-reactive proteinFCFold changeFDRFalse Discovery rateGFRGlomerular filtration rateGGTGamma-glutamyl transferaseGlycGlycoproteinsGOTGlutamate-oxalacetate-transferaseHCHealthy cohortLeukLeucozytesLDHLactat dehydrogenaseNMRNuclear magnetic resonanceSPCSupramolecular phospholipid compositeT2DMDiabetes mellitus Type 2TMAOTrimethylamine-N-oxidePACSPost-acute-covid-syndromPCAPrincipal component analysisRAASIRenin-angiotensin-aldosterone-system inhibitors